I have been through one internal appeal already and would like to do the next one properly.
I understand the observation; what I do not understand is the mechanism behind it.
I have read the two review articles that come up first and both assert this without a citation to a primary source.
So what is the mechanism, and how well established is it?
The honest answer is that a well-run compounding pharmacy is a serious operation and that the variance across facilities is wide.
Regulators generally prohibit compounding what is essentially a copy of a commercially available product, with a shortage listing being the usual exception that permits it temporarily.
| Line | Brand, insured | Compounded, subscription | Research-grade, self-tested |
|---|---|---|---|
| Product | Copay × 12 | Monthly fee × 12 | Vials × unit price |
| Consultation | Covered or copay | Bundled | Not applicable |
| Monitoring labs | Often covered | Usually not | Self-funded |
| Independent testing | Not applicable | Optional | Essential; per lot |
| Shipping | Pharmacy | Included | Per order |
| Dominant cost | Copay structure | Subscription fee | Testing |
In practice, facility quality varies enormously and is the practical determinant of what you receive. The relevant questions are about sterility assurance, potency testing and beyond-use dating.
Compounding is defined in regulation as preparation for an individual patient under prescription and is distinguished from manufacturing by scale and by the patient-specific requirement.
Ask for the certificate of analysis on the lot. A serious facility has one.
edited 30 Mar 2026 by assay_blank — added the method parameters
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemCopies of commercially available products are generally not permitted, which is the constraint that shapes most of this market.
Beyond-use dates on compounded sterile preparations are set by standards that depend on the preparation environment and are much shorter than a manufactured product's shelf life.
Ask for the certificate of analysis on the compounded lot. A serious facility will have one; the request itself is informative.
Beyond-use dating for compounded sterile preparations is governed by published standards keyed to the compounding environment.
Check the beyond-use date and what it was based on.
Answer first: a compounded preparation is made for an individual under a prescription and is not an approved product, so it carries neither the release testing nor the pharmacovigilance of one.
Compounding is the preparation of a medicine for an individual patient in response to a prescription, where an approved product is unsuitable. It sits outside the approval framework by design rather than by omission.
The part that matters: a compounded preparation has no marketing authorisation, no batch release by a qualified person and no pharmacovigilance obligation attached to it. That is the structural difference from a licensed product.
Regulatory warnings have specifically addressed salt forms differing from the approved active moiety in this therapeutic area.
Compounded means unapproved by definition. That is structural, not pejorative.
Start with the regulatory basis, because compounding is permitted under specific conditions and those conditions are the whole subject.
Additives are the other divergence. Preparations combining an active with vitamins or other agents are not equivalent to the approved product and have not been studied in that combination.
Prohibitions on compounding essential copies of commercially available products are explicit in the relevant regulatory frameworks, with shortage listings as the usual exception.
The caveat is that the legal and regulatory position differs by jurisdiction and nothing here is legal advice.
Ask which salt form. A different salt is a different active moiety.
The relevant distinction is between compounding for an individual patient and compounding at scale, which are regulated differently.
Salt forms matter: a compounded preparation using a different salt from the approved product is not the same active moiety, and that has been the specific object of regulatory warnings.
A compounded preparation is unapproved by definition, which is a statement about the framework rather than about the facility.
The framework is jurisdiction-specific. Check yours rather than a general answer.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.